PRDM9 and central nervous system cancer: Recently, Ghildiyal and Sen (2017) reported that histone methyltransferase G9a that regulated H3K9 dimethylation has also correlated with the development and progression of glioma, and its inhibitors have also been reported as potential agents for the treatment of glioma (Guo et al., 2016).